Veru’s (VERU) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Veru (NASDAQ:VERU) in a report released on Friday morning,Benzinga reports. They currently have a $3.00 price objective on the stock.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $5.00 price target on shares of Veru in a report on Tuesday, November 5th.

Veru Price Performance

VERU stock opened at $0.65 on Friday. Veru has a 12 month low of $0.36 and a 12 month high of $1.92. The firm has a market capitalization of $95.15 million, a PE ratio of -1.35 and a beta of -0.50. The company’s 50 day simple moving average is $0.74 and its 200-day simple moving average is $0.82.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. As a group, sell-side analysts anticipate that Veru will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Veru

Institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its position in Veru by 26.5% during the 2nd quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock worth $5,942,000 after purchasing an additional 1,478,578 shares during the period. PVG Asset Management Corp acquired a new stake in Veru during the 2nd quarter valued at approximately $474,000. Bank of New York Mellon Corp grew its stake in Veru by 1,718.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock valued at $373,000 after purchasing an additional 419,374 shares in the last quarter. Choreo LLC raised its position in shares of Veru by 261.3% in the 2nd quarter. Choreo LLC now owns 332,050 shares of the company’s stock valued at $292,000 after purchasing an additional 240,134 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Veru during the 2nd quarter valued at approximately $161,000. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.